GLP-1 Grug: How to authoritatively explain Semaglutide？
-By Polypeptide.ltd
Semaglutide Peptide Structure
Authoritative source：PubChem
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
Introduction Semaglutide is a medication used for the treatment of type 2 diabetes and for long-term weight management in individuals with obesity or excess weight. It is a peptide drug known as glucagon-like peptide-1(GLP-1) receptor agonists and designed to mimic the action of GLP-1 hormone, which is released in the gut after eating. Semaglutide works by helping the pancreas release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar in the blood to other body tissues where it is used for energy. Semaglutide injection also slows the movement of food through the stomach, which may decrease appetite and cause weight loss. Three are three brands of Semaglutide for sale in the market currently, Ozempic, Wegovy and Rybelsus.
Mechanism of Semaglutide As a glucagon-like peptide-1(GLP-1) receptor agonist, Semaglutide plays its role to lower blood sugar level by binding to GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion and reduce the release of glucagon, aiding in glucose uptake. In addition, the drug slows gastric emptying, promoting prolonged satiety and controlled nutrient absorption. This enhances high satiety and reduces appetite, promoting the interaction of semaglutide with GLP-1 receptors in the brain.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
Authoritative source：Wiki These mechanisms collectively contribute to improved blood sugar control, reduced appetite and sustainable weight loss, making more and more people buying Semaglutide for both diabetes management and long-term weight management.
Benefits of Semaglutide As the demand and interest in Semaglutide peptide grows, so does the research on it. Not only does Semaglutide offer multiple benefits for people with type 2 diabetes and those seeking to manage their weight, it also has potential effects in the treatment of fatty liver disease and cognitive brain disorders. Specific benefits may vary depending on the condition being treated. Here are the main benefits of using Semaglutide powder: Semaglutide injection for Type 2 Diabetes Treatment: Semaglutide is currently approved as a type 2 diabetes (T2D) treatment. After injection of Semaglutide, the active ingredient of Semaglutide mimics the human GLP-1 hormone. Helps regulate blood sugar levels by increasing insulin secretion and decreasing glucagon production. This allows for better blood sugar control and reduces the risk of high blood sugar. Simultaneously, Semaglutide has been shown to reduce HbA1c levels, which is a marker of average blood sugar levels over time. Lowering HbA1c reduces the risk of diabetes-related complications. Semaglutide has demonstrated a relatively low risk of hypoglycemic events compared with other antidiabetic drugs. Semaglutide injection for Weight Loss: Semaglutide is also approved as a weight management treatment. Study Shows Semaglutide Effective as Weight Loss Drug in Both Diabetic and Non-Diabetic People. According to research, after injection of Semaglutide, it will increase satiety and suppress appetite to achieve anti-obesity effect. According to one 68-week study, adults who injected Semaglutide lost an average of 35 pounds, or 15 percent of their total body weight. If you have been battling obesity or are overweight and have not been successful with lifestyle changes alone, Semaglutide may provide the extra support you need. Plus, you’ll get great prices on buying Semaglutide powder in bulk. Semaglutide injection for Cardiovascular Risk: As a hot sale weight-loss drug on the market, the breakthrough of Semaglutide lies not only in the weight-loss effect itself, but also in its ability to indirectly regulate body weight and directly act on the cardiovascular system. It can show comprehensive cardiovascular health benefits for obese people and T2DM people . Research shows that Semaglutide has significant effects of lowering blood sugar, promoting weight
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
loss, lowering blood pressure, and lowering blood fat. These effects indirectly contribute to cardiovascular protection. Obesity is an important factor in the development of various health problems, including abnormal blood lipid levels, type 2 diabetes mellitus (T2DM), high blood pressure and obstructive sleep apnea. These conditions increase the likelihood of cardiovascular disease, which remains the leading cause of death worldwide. Therefore, it is crucial to address overweight in overweight or obese individuals to prevent cardiovascular disease.
Authoritative source：Wiki Other Potential Benefits of Semaglutide injection: As people's research on Semaglutide continues to deepen, the benefits of Semaglutide are also emerging in front of people. In addition to effectively treating diabetes and weight management, Semaglutide also shows great potential in treating or preventing cognitive decline and dementia, treating cancer and fatty liver, and anti-inflammation. ❶Semaglutide for Cognitive Decline and Dementia: The impact of obesity in midlife on dementia in later life has been proven. Research shows that people who are overweight or obese have a higher risk of developing dementia in the future, and that treating obesity early in life can help reduce dementia risk. In addition to its approved use for weight loss and hypoglycemia, Semaglutide also shows promise in the fields of anticancer and neurodegeneration. It has attracted attention for its potential in alleviating neurodegenerative diseases. GLP-1 is a natural hormone that regulates blood sugar and a neurotransmitter whose receptors are expressed in various regions of the brain.Studies have shown a significant reduction in the incidence of dementia in individuals taking GLP-1 receptor agonists. ❷Semaglutide for Cancer: A study recently published in the journal Obesity shows that these
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
long-acting glucagon-like peptide-1 (GLP-1) receptor agonist can reverse the impaired function of natural killer cells (NK cells) in obese patients, which This change was not caused by weight loss. Researchers at Maynooth University in Ireland carried out the study involving 20 obese patients. They found that the GLP-1 analog restored the function of natural killer cells, the white blood cells responsible for fighting viruses and cancer cells. Other studies have shown that GLP-1 regulates macrophages, natural killer cells and T cells. GLP-1 treatment directly improves NK cell cytokine production and metabolic activity, potentially providing the broader advantages of this class of drugs in obese patients. ❸Semaglutide for fatty liver: Nonalcoholic fatty liver disease (NAFLD) is a progressive disease that initially manifests as simple steatosis (nonalcoholic fatty liver disease or NAFL). Over time, it can develop into a more complex form called nonalcoholic steatohepatitis (NASH), which is characterized by steatosis, inflammation and fibrosis. If left untreated, NASH can progress to cirrhosis and, in some cases, hepatocellular carcinoma (HCC). Studies have shown that GLP-1RA (glucagon-like peptide-1 receptor agonist) is effective in reducing transaminase levels and liver fat content in patients with T2DM and NAFLD. Semaglutide is the latest generation of GLP-1RA, which can not only lower blood sugar and promote weight loss, but also improve various cardiovascular risk factors. In addition, studies have shown that GLP-1RA can reduce liver fat content in patients with type 2 diabetes, suggesting its potential to improve fatty liver conditions. GLP-1RA shows promise in the treatment of NAFLD. For patients with both T2DM and NAFLD, especially those who are overweight or obese, initiation of semaglutide therapy may be considered. Semaglutide not only helps control blood sugar and promote weight loss, but also improves fatty liver and liver metabolism, thereby enhancing liver function, patient compliance, treatment compliance and quality of life. ❹Semaglutide for Inflammation: Inflammation is an important response to challenges such as infection and tissue repair. However, chronic inflammation has been linked to diseases like type 2 diabetes, metabolic syndrome, obesity, cancer, and more. Recent studies have shown that GLP-1 and its analogs can attenuate inflammatory responses in animal models. It should be noted that the effects of Semaglutide are maximized when combined with a nutritious diet, regular physical activity, and ongoing medical supervision. As with any drug, potential adverse and personal reactions should be evaluated and discussed with a healthcare professional.
Side effects of Semaglutide Injections Most Semaglutide side effects are mild and transient when prescribed and supervised by a healthcare professional.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
When Semaglutide is injected, swelling/redness/itching at the injection site, tiredness, nausea, vomiting, diarrhea, or constipation may occur. Nausea usually decreases as you continue to use Semaglutide. If these effects persist or get worse, talk to your doctor right away. Although Semaglutide does not cause hypoglycemia, there is a risk of hypoglycemia when it is used with certain diabetes medications. Pregnant and lactating patients are generally advised not to use Semaglutide.
Reference citations [1] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group.”Once-Weekly Semaglutide in Adults with Overweight or Obesity.”N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.PMID: 33567185 [2] Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators.”Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.”JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.PMID: 35015037 [3] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators.”Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.”N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.PMID: 34170647 [4] Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators.”Once-Weekly Semaglutide in Adolescents with Obesity.”N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601. Epub 2022 Nov 2.PMID: 36322838 [5] Smits MM, Van Raalte DH.”Safety of Semaglutide.”Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.PMID: 34305810 [6] Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators.”Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.”JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.PMID: 33755728 [7] O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH.”Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.”Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.PMID: 30122305 [8 ]Chao AM, Tronieri JS, Amaro A, Wadden TA.”Semaglutide for the treatment of obesity.”Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21.PMID: 34942372 [9] Singh G, Krauthamer M, Bjalme-Evans M.”Wegovy (semaglutide): a new weight loss drug for chronic weight management.”J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27.PMID: 34706925 [10] Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators.”Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.”JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.PMID: 33625476 [11] Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN.”Semaglutide as a promising antiobesity drug.”Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.PMID: 30768766 [12] Meier JJ.”Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.”Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617. eCollection 2021.PMID: 34248838 [13] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group.”Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.”Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.PMID: 36216945 [14] Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators.”Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.”N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.PMID: 31185157 [15] Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group.”Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.”Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.PMID: 35441470
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/